- The first and only weekly oral NSAID, for consistent OA pain and
inflammation management.
- Indicated for the treatment of pain and inflammation associated
with osteoarthritis (or degenerative joint disease) in dogs.
- The first and only weekly oral NSAID
- A novel answer to canine OA and breakthrough pain management
- Plasma levels remain stable at the required therapeutic level for
7 days1
- Licensed for all stages of OA
- Can be given continuously, with no risk of over-accumulation or
requirement for mandatory treatment breaks
- After treatment with Daxocox vets reported that 74% of dogs don#t
show clinical signs of OA2
- Owners reported, after treatment, that 84% of dogs improved their
quality of life from #poor or fair# to #good, very good or excellent#2
1. Internal report: PK_001_2018, pending publication
2. Internal report: DA
197
C, pending publication
£20.98
Click here to find expanded datasheet with further product information